



SOUTH CAROLINA REVENUE AND FISCAL AFFAIRS OFFICE
STATEMENT OF ESTIMATED FISCAL IMPACT
 (803)734-0640 • RFA.SC.GOV/IMPACTS

Bill Number: S. 0918 Introduced on January 23, 2018
Author: Peeler
Subject: Prescription Reports
Requestor: Senate Medical Affairs
RFA Analyst(s): A. Martin
Impact Date: March 15, 2018 - Updated for Additional Agency Response

Estimate of Fiscal Impact

	FY 2018-19	FY 2019-20
State Expenditure		
General Fund	\$0	\$0
Other and Federal	\$0	\$0
Full-Time Equivalent Position(s)	0.00	0.00
State Revenue		
General Fund	\$0	\$0
Other and Federal	\$0	\$0
Local Expenditure	\$0	\$0
Local Revenue	\$0	\$0

Fiscal Impact Summary

This bill will have no impact on the General Fund, Federal Funds, or Other Funds because this bill does not materially alter the oversight or regulatory duties of the Department of Labor, Licensing and Regulation (LLR) or the Department of Health and Environmental Control (DHEC). This fiscal impact statement has been updated based on a response from DHEC.

Explanation of Fiscal Impact

Updated for Additional Agency Response

Introduced on January 23, 2018

State Expenditure

This bill defines “targeted controlled substance” to mean any Schedule II or III controlled substance. In addition, this bill requires the use of electronic prescriptions, with exceptions, when prescribing targeted controlled substances, and establishes quantity limitations on such prescriptions.

As part of the prescription monitoring program, DHEC is required to develop and maintain a system to provide prescription reports to practitioners to inform them of certain prescribing trends. This will require DHEC to coordinate with, at minimum, the Board of Medical Examiners to develop and implement a prescription report card program beginning January 1, 2019. Beginning February 1, 2019, DHEC will be required to report to various state agencies on the data reported to the prescription monitoring program during the preceding calendar year. DHEC currently maintains the state’s prescription monitoring program.

Beginning in 2020, DHEC will be required to conduct periodic audits of the review of the prescription monitoring program by practitioner. DHEC will be required to report to the appropriate board any practitioner that is found to be in violation of the requirement to review a patient's prescription history before issuing a prescription for a Schedule II controlled substance.

This bill adds the patient phone number and the method of payment for the prescription to the list of information a practitioner must submit to DHEC's Bureau of Drug Control when delivering a controlled substance. This information is currently not included in the prescription monitoring program.

This bill requires any person dispensing a Schedule II-IV controlled substance to review the patient's information in the prescription monitoring program for at least the preceding twelve-month period before dispensing a targeted controlled substance. In addition, this bill sets forth certain circumstances upon which the dispenser must document their review. Currently, only the practitioner is responsible for reviewing a patient's information in the prescription monitoring program. This review is only required when issuing a prescription for a Schedule II controlled substance, and there is no specified look-back period. In addition, pharmacists are expressly excluded from the review requirement.

Department of Health and Environmental Control. This bill charges DHEC with additional responsibilities that the agency is able to manage within existing appropriations. Therefore, this bill will have no expenditure impact on the General Fund, Federal Funds, or Other Funds. This fiscal impact statement has been updated based on a response from DHEC.

Department of Labor, Licensing and Regulation. While this bill creates additional duties for practitioners, pharmacists, and other licensed professionals, it does not alter the activities of the related boards. Therefore, this bill will have no expenditure impact on the General Fund, Federal Funds, or Other Funds.

State Revenue

N/A

Local Expenditure

N/A

Local Revenue

N/A

Introduced on January 23, 2018

State Expenditure

This bill defines "targeted controlled substance" to mean any Schedule II or III controlled substance. In addition, this bill requires the use of electronic prescriptions, with exceptions, when prescribing targeted controlled substances, and establishes quantity limitations on such prescriptions.

As part of the prescription monitoring program, DHEC is required to develop and maintain a system to provide prescription reports to practitioners to inform them of certain prescribing trends. This will require DHEC to coordinate with, at minimum, the Board of Medical Examiners to develop and implement a prescription report card program beginning January 1,

2019. Beginning February 1, 2019, DHEC will be required to report to various state agencies on the data reported to the prescription monitoring program during the preceding calendar year. DHEC currently maintains the state's prescription monitoring program.

Beginning in 2020, DHEC will be required to conduct periodic audits of the review of the prescription monitoring program by practitioner. DHEC will be required to report to the appropriate board any practitioner that is found to be in violation of the requirement to review a patient's prescription history before issuing a prescription for a Schedule II controlled substance.

This bill adds the patient phone number and the method of payment for the prescription to the list of information a practitioner must submit to DHEC's Bureau of Drug Control when delivering a controlled substance. This information is currently not included in the prescription monitoring program.

This bill requires any person dispensing a Schedule II-IV controlled substance to review the patient's information in the prescription monitoring program for at least the preceding twelve-month period before dispensing a targeted controlled substance. In addition, this bill sets forth certain circumstances upon which the dispenser must document their review. Currently, only the practitioner is responsible for reviewing a patient's information in the prescription monitoring program. This review is only required when issuing a prescription for a Schedule II controlled substance, and there is no specified look-back period. In addition, pharmacists are expressly excluded from the review requirement.

Department of Health and Environmental Control. The expenditure impact of this bill is pending, contingent upon a response from DHEC.

Department of Labor, Licensing and Regulation. While this bill creates additional duties for practitioners, pharmacists, and other licensed professionals, it does not alter the activities of the related boards. Therefore, this bill will have no expenditure impact on the General Fund, Federal Funds, or Other Funds.

State Revenue

N/A

Local Expenditure

N/A

Local Revenue

N/A



Frank A. Rainwater, Executive Director